ClearPoint Neuro, Inc.

NASDAQ:CLPT

Medical - Devices

Healthcare
$7.71 +5.30%

+$0.89 today

Market cap
$247.14M
Beta
1.31
P/E (TTM)
-18.0
EPS (TTM)
-$0.98
52W Low $8.27High $30.10

Volume 0.64M

Average 0.67M

CLPT Stock-Based Compensation

Employee pay granted in shares or options; a non-cash expense that dilutes existing shareholders.

ClearPoint Neuro, Inc.NASDAQ: CLPT

Stock-Based Compensation · Q1 FY2026 · quarter ended Mar 2026

Stock-based compensation grows in line with its trailing trend

Q1 FY2026 stock-based compensation of $2.22M rose 16.2% year over year, in line with the +16.1% change in trailing-twelve-month stock-based compensation. Sequentially, it rose 12.0% from the prior quarter. Over 3 fiscal years it compounded at +25.6% a year.

Context

  • Stock-based compensation amounted to 22.1% of revenue in FY2025, up 0.1 pp from a year earlier.
  • Stock-based compensation increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +16.2% holds above the trailing-twelve-month pace of +16.1%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
$2.22M+12.0% QoQ
Last fiscal yearDec 2025
$8.18M+18.4% YoY
LTMMar 2026
$8.49M+16.1% YoY
Stock-Based Compensation past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+16.2%——
1 year+18.4%——
3-year CAGR+25.6%——
5-year CAGR——
10-year CAGR——

Stock-Based Compensation history

USD · from the cash flow

Latest · FY2025
8.18M USD
Year-over-year change
+18.4%
4-year CAGR
+40.9%

Stock-Based Compensation vs competitors

How CLPT compares with its peers on the latest reported figures

  • Peers report in different currencies, so stock-based compensation is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +16.1% is the 3rd highest of 10, against a peer median of -10.7%.
  • Stock-based compensation amounts to 20.9% of revenue for CLPT, versus a peer median of 5.3%.
CLPT Competitors
Stock-Based Compensation for CLPT and competitors
Company Period LTM YoY 3-year CAGR% of revenue
OFIXOrthofix Medical Inc.LTM Mar 2026$42.3M USD+40.4%+15.9%5.1%
LABStandard BioTools Inc.LTM Mar 2026$27.48M USD-5.7%+25.8%31.9%
SIBNSI-BONE, Inc.LTM Mar 2026$24.89M USD-2.4%+3.4%12.1%
CTKBCytek Biosciences, Inc.LTM Mar 2026$22.82M USD-18.0%+14.0%11.2%
SNDLSNDL Inc.LTM Mar 2026CA$13.13M CAD-20.8%+12.9%1.4%
AKBAAkebia Therapeutics, Inc.LTM Mar 2026$12.76M USD+67.9%-14.2%5.5%
CMPSCOMPASS Pathways plcLTM Mar 2026$12.55M USD-31.5%+1.2%—
AVNSAvanos Medical, Inc.LTM Mar 2026$12.5M USD-10.7%-7.5%1.7%
VREXVarex Imaging CorporationLTM Apr 2026$10.9M USD-28.8%+2.3%1.3%
CLPTClearPoint Neuro, Inc.LTM Mar 2026$8.49M USD+16.1%+25.6%20.9%
Peer median (excluding CLPT) —-10.7%+3.4%5.3%

Competitors are the stored peer set for CLPT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(14.41M)(16.43M)(22.09M)(18.91M)(25.54M)
Depreciation & Amortization692K777K1.51M1.9M982K
Deferred Income Tax202K0000
Stock-Based Compensation2.08M4.13M6.08M6.91M8.18M
Change in Working Capital(1.68M)(4.29M)(1.4M)1.4M(9.81M)
Accounts Receivables627K(211K)(1.8M)(1.21M)(268K)
Inventory(1.71M)(4.42M)1.25M743K(103K)
Accounts Payables(762K)1.59M03.11M(7.52M)
Other Working Capital165K(1.25M)(846K)(1.24M)(1.92M)
Other Non-Cash Items425K3.78M2.18M(245K)2.27M
Operating Cash Flow(12.7M)(16.17M)(13.72M)(8.95M)(23.93M)
Capital Expenditures(168K)(253K)(717K)(275K)(522K)
Acquisitions (Net)00001.14M
Purchases of Investments0(21.59M)000
Sales of Investments012M000
Other Investing Activities009.67M00
Investing Cash Flow(168K)(10.74M)8.95M(275K)615K
Debt Repayment000(10M)48.09M
Common Stock Issued46.79M745K016.15M3.95M
Common Stock Repurchased00(210K)00
Dividends Paid00000
Other Financing Activities90K(336K)506K40K(1.86M)
Financing Cash Flow46.88M409K296K6.19M50.18M
Effect of Forex Changes00000
Net Change in Cash34.01M(26.49M)(4.48M)(3.04M)26.87M
Free Cash Flow(12.87M)(16.42M)(14.44M)(9.23M)(24.45M)

ClearPoint Neuro, Inc.

NASDAQ:CLPT

Intrinsic Alpha fair value

Locked

Current Price

$7.71

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.